Expression data from OMP52M51 resistant or acute treated leukemic mice

We recently demonstrated that a human Notch1-specific neutralizing antibody (OMP52M51) was very effective in T-ALL patient derived xenografts (PDX) bearing NOTCH1/FBW7 mutations. However, we observed development of acquired resistance following long-term administration of the antibody and used PDX models to investigate this phenomenon. We analyzed expression profiles to identify genes and pathways modulated in mice treated until progression or acute treated with a neutralizing antibody against Notch1. Cells were recovered from spleens of control (Ctrl Ab), resistant (OMP52M51 resistant) or acute treated (acute) mice for RNA extraction and hybridization on Affymetrix microarrays. Each sample derived from a different mouse (3-5 mice/group).